Single Short Retention Instillation of Pirarubicin Prevents Intravesical Recurrence of Low-risk Non Muscle Invasive Bladder Cancer
Single Short Retention Instillation of Pirarubicin Prevents Intravesical Recurrence of Low-risk Non Muscle Invasive Bladder Cancer
复制标题
DOI：
10.21873/invivo.12360
复制
发表时间：
2021-03-01
期刊：
影响因子：
2.3
通讯作者：
Kawauchi, Akihiro
中科院分区：
文献类型：
--
作者：
Kageyama, Susumu;Maeda, Koki;Kawauchi, Akihiro
背景资料：本研究评价了吡拉罗酮单次滴注（保留时间短）预防低风险非肌层浸润性膀胱癌膀胱内复发的疗效。患者和方法：我们分析了165例接受经尿道手术的低风险非肌层浸润性膀胱癌患者。在47例（28%）患者中，术后立即单次滴注吡拉西坦，保留时间为15分钟。其他患者（118例，72%）未接受滴注治疗。主要终点是无复发生存期。结果：中位总体随访时间为50个月（范围=6-134）。吡拉西坦治疗组和单纯手术治疗组的1年和5年无复发生存率分别为91%和72%，79%和54%（p=0.031）。考克斯风险分析显示，缺乏灌注和较大的肿瘤大小（>10 mm）是复发风险的重要因素。未观察到与膀胱内化疗相关的不良事件。结论：吡拉韦15 min内灌注可预防低危膀胱肿瘤术后复发。
Background: This study evaluated the efficacy of a single instillation of pirarubicin with a short retention time for preventing intravesical recurrence of low-risk non-muscle-invasive bladder cancer. Patients and Methods: We analyzed 165 patients with low-risk non-muscle-invasive bladder cancer who underwent transurethral surgery. Single instillation of pirarubicin with 15-min retention time immediate after surgery was performed in 47 (28%) patients. The other patients (118, 72%) were treated without instillation therapy. The primary endpoint was recurrence-free survival. Results: Median overall follow-up was 50 (range=6-134) months. Recurrence-free survival at 1 and 5 years was 91% and 72%, and 79% and 54% in the group treated with pirarubicin, and that treated with surgery alone, respectively (p=0.031). Cox's hazard analysis revealed lack of instillation and larger tumor size (>10 mm) as significant factors for risk of recurrence. No adverse events regarding intravesical chemotherapy were observed. Conclusion: Pirarubicin instillation with 15-min retention time can prevent intravesical recurrence of low-risk bladder tumors.